NASDAQ:BNR

Burning Rock Biotech Stock Insider Trading

Healthcare > Medical - Diagnostics & Research

Buy BNR

*Your capital is at risk

$10.66

-0.640 (-5.66%)

At Close: Jul 13, 2026

Burning Rock Biotech Stock Insider Power

Based on the 21 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 2.44M and sold 0 BNR shares in the last 21 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 21 transactions)	100.00
● Buy	2.44M shares
● Sell	0 shares
100% Buy Activity Weak Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 26, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	24 900 Value: $199.1K
Jun 24, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	250 000 Value: $2.00M
Jun 23, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	5 990 Value: $44.9K
Jun 22, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	104 650 Value: $779.7K
Jun 16, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	111 110 Value: $1,000.0K
Jun 12, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	210 000 Value: $1.94M
Jun 11, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	24 760 Value: $216.4K
Mar 31, 2026 Buy	Ordinary Shares (represented by American depositary shares) P-Purchase	Han Yusheng Director	Director	314 870 Value: $5.47M
Mar 18, 2026 Buy	Ordinary Shares	Deng Feng Director	Director	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Deng Feng Director	Director	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Deng Feng Director	Director	0 Value: $0
Mar 17, 2026 Buy	Common Stock J-Other	Hayes Wendy W. Insider	Other	0 Value: $0
Mar 17, 2026 Buy	Ordinary Shares	Han Yusheng Director	Director	0 Value: $0
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Han Yusheng Director	Director	1 059 797 Value: $3.53M
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Han Yusheng Director	Director	116 000 Value: $23
Mar 17, 2026 Buy	Ordinary Shares	Zhang Zhihong Director	Director	0 Value: $0
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Zhang Zhihong Director	Director	117 755 Value: $392.1K
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Zhang Zhihong Director	Director	56 000 Value: $11
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Hu Xiaozhi Senior Director In Finance	Officer	36 000 Value: $7
Mar 17, 2026 Buy	OPTIONS (RIGHT TO BUY)	Hu Xiaozhi Senior Director In Finance	Officer	11 776 Value: $39.2K
Mar 17, 2026 Buy	Ordinary Shares	Xu Licen Lisa Director	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BURNING ROCK BIOTECH LIMITED

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestina...

Read Full Profile Here